Orlando, FL -- (SBWIRE) -- 09/24/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Caterpillar Inc. (NYSE:CAT), Gilead Sciences, Inc.(NASDAQ:GILD).
Caterpillar Inc. (NYSE:CAT) stock jumped 0.33% to $85.03. The company on Sept. 20 reported weaker sales by its dealers for the three months ended Aug. 31. The company said world-wide sales of machinery were down 10% in the latest three months from a year earlier, while sales of engines, or "power systems," fell 6%.
In the three months ended July 31, machinery sales were down 9% and engines were unchanged from a year before.
Additionally, the company on August 21 announced its sponsorship of the 2013 High Horsepower Summit (HHP) Summit, September 17-19 in Chicago, Illinois. This technology and end-user conference is North America's leading conference on the use of natural gas to fuel high horsepower operations.
Moreover, theStreet reaffirmed their buy rating on shares of Caterpillar (NYSE:CAT) in a report issued on August 9. Separately, analysts at Zacks downgraded shares of Caterpillar from a neutral rating to an underperform rating in a research note to investors onFriday, August 2nd. They now have a $77.00 price target on the stock.
Are investors worried about the recent updates with CAT? Find out with a free trend analysis HERE
Gilead Sciences, Inc.(NASDAQ:GILD) shares declined 2% to $62.58. Analysts at Ameriprise Financial assumed coverage on shares of Gilead Sciences in a research report issued to clients and investors on Sept. 19. The firm set a “buy” rating on the stock.
Additionally, the company on Sept. 12 announced 48-week results from a Phase 2 study (Study 102) evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection. At 48 weeks, a regimen of elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/TAF 10 mg was found to be similar to Stribild® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) based on the percentage of patients with HIV RNA levels less than 50 copies/mL, and was associated with more favorable renal and bone safety markers.
Is GILD going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)